Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of chronic lymphocytic leukemia requiring therapy~* Previously treated with ≥ 1 chemotherapeutic regimen~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Life expectancy ≥ 12 weeks~* Creatinine clearance ≥ 30 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile female patients must use effective contraception for 4 weeks before, during, and for 6 months after completion of study treatment~* Fertile male patients must use effective contraception during and for 6 months after completion of study treatment~* No history of anaphylaxis after exposure to rat or mouse-derived complementary-determining region (CDR)-grafted humanized monoclonal antibodies~* No toxicity attributable to purine analogues (e.g., autoimmune hemolytic anemia, neurological toxicity, or allergy)~* No active infection~* No other severe (particularly cardiac or pulmonary) diseases or mental disorders that would preclude study participation~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior fludarabine (or other purine analogues) combined with cyclophosphamide and mitoxantrone hydrochloride~* No prior rituximab, either alone or in combination with chemotherapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).